Checkpoint Therapeutics to Participate in the B. Riley Securities’ Virtual Oncology Conference
January 25, 2022 16:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...
Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
January 25, 2022 07:30 ET
|
Checkpoint Therapeutics, Inc
Study met primary endpoint with 47.4% objective response rateSafety and tolerability profile consistent with previously reported dataPlanned BLA submission on track for later this yearConference call...
Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer
December 08, 2021 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the...
Checkpoint Therapeutics Reports Third Quarter 2021 Financial Results
November 04, 2021 16:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference
September 22, 2021 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...
Checkpoint Therapeutics to Participate in Two Upcoming Investor Conferences
September 09, 2021 08:30 ET
|
Checkpoint Therapeutics, Inc
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that...
Checkpoint Therapeutics Reports Second Quarter 2021 Financial Results
August 05, 2021 16:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...
Checkpoint Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference
July 08, 2021 08:30 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James...
Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma
May 12, 2021 08:00 ET
|
Checkpoint Therapeutics, Inc
Top-line results expected in 4Q 2021Targeting BLA submission in 1H 2022Market-disruptive pricing planned in $25 billion and growing PD-(L)1 market NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) --...
Checkpoint Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Highlights
May 06, 2021 16:15 ET
|
Checkpoint Therapeutics, Inc
NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial...